Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

ent of metastatic breast cancer and is also in Phase 2 studies for the treatment of lung and brain cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia. Additional late-stage development products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a longer-acting rFVIII program, which is in Phase 3 clinical development for patients with hemophilia A.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com

*Sources: Bell TJ et. al. Pain Med 2009;10(1):35-42, Hess B et. al. Eur J Intern Med 2011;22(5):527-531, Rosti G et. al Eur Rev Med Pharmacol Sci. 2010;14(12):1045-1050. Galvez R et. al. Aten Primaria 2014;46(1):32-39, Droney J et. al. Support Care Cancer 2008;16(5):453-459.

Movantik is a trademark of AstraZeneca.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential regulatory approval of Movantik&
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... fourth quarter and full year ended December 31, 2014. ... PTC. We are now a growing commercial-stage biopharma company, ... rare disease space," stated Stuart W. Peltz, Ph.D., Chief ... bring the first treatment for Duchenne muscular dystrophy to ...
(Date:2/27/2015)... TEL-AVIV, Israel , February 27, 2015 ... Unternehmen baut sein bahnbrechendes Überwachungssystem für kongestive ... weiter aus -   ... Medical Technologies, die ein neuartiges Herzüberwachungssystem für ... gab heute bekannt, dass sie ein Finanzierungsvorhaben ...
(Date:2/27/2015)... -- Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... Bionik Laboratories, Inc., a Toronto ... accredited investors of units consisting of its common stock ... million. Shares of the Company,s common stock will continue ... symbol "DWTPD" until FINRA,s approval of the ticker "BNKL." ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... SAN DIEGO, March 1, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... present at the following investor conferences: Citi 2011 ... 10:00 a.m. Eastern Time at the Hilton New York Hotel ... Health Care Conference on Monday, March 7, 2011 at 4:45 ...
... March 1, 2011 Valeritas, Inc., ... and commercialization of innovative drug delivery solutions, announced ... has cleared the company,s V-Go Disposable Insulin Delivery ... the continuous subcutaneous delivery of insulin in preset ...
Cached Medicine Technology:Optimer Pharmaceuticals to Present at March 2011 Investor Conferences 2Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog® 2Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog® 3
(Date:2/27/2015)... 27, 2015 Mediaplanet today announces the ... a campaign that aims to bring blood health and ... conversation. The stories in this edition go beyond the ... clinical care, hard-hitting advocacy, research and technological strides needed ... the American Cancer Society, approximately every 3 minutes ...
(Date:2/27/2015)... TN (PRWEB) February 27, 2015 The ... Health, has announced a scholarship for rising freshmen undergraduate ... Nashville’s leading periodontist office specializing in many periodontal procedures ... and treatment of gum disease . In honor ... $1,000 college scholarship for eligible rising freshmen undergraduate students. ...
(Date:2/27/2015)... 27, 2015 Insight Accelerator Labs ... advance the development of an in-line urine flow ... is being developed in direct response to current ... accuracy and error margins with potentially grave consequences. ... measurement and provide trending data analysis to signal ...
(Date:2/27/2015)... Mirena IUD lawsuits ( http://www.mirenalawsuit2014.com/ ) ... uterine perforations and other serious harm due to spontaneous ... forward in the multicounty litigation underway in New Jersey’s ... Court records indicate that the proceeding’s 34th Case Management ... convened that same day. (In Re: Mirena Litigation; Case ...
(Date:2/27/2015)... Over 440,000 patients die annually as a ... two jumbo jet airplanes crashing each day. Now more than ... an effort to do all they can to stay safe. ... the 17th U.S. Surgeon General, discusses the importance of safer ... to address safety issues to ensure that all our patients ...
Breaking Medicine News(10 mins):Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2Health News:Nashville Periodontist Office AIOH Announces 2015 Scholarship 2Health News:Output Medical Joins Insight Accelerator Labs 2Health News:Output Medical Joins Insight Accelerator Labs 3Health News:Mirena Lawsuits Progress in New Jersey with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Progress in New Jersey with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports 3Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2
... News) -- Average annual premiums for employer-sponsored family health coverage ... than $15,000, according to new research from the Kaiser Family ... average, U.S. workers now pay more than $4,000 each year ... in workers, wages, the 2011 employer health benefits survey found. ...
... The Austen BioInnovation Institute in Akron (ABIA), its founding members ... $500,000 award to fund the Accountable Care Community (ACC) initiative, ... today. ACC is a collective effort aiming to create ... the Akron region. The funding is part of ...
... research suggests that the modern day-day-night-night shift pattern for ... potentially carcinogenic as older, more extreme shift patterns. ... risk of cancer, although the biological mechanism responsible for ... paper,s lead author and a doctoral student in the ...
... Brinster of the University of Pennsylvania School of Veterinary ... according to an announcement today from the White House. ... United States government on scientists and engineers. Brinster, ... Penn Vet, is the first veterinarian and the seventh ...
... (HealthDay News) -- Older, overweight women have about the same ... when their leg strength and power was assessed relative to ... of normal weight, a new study has found. The ... likely to become disabled due to the loss of muscle ...
... Mozes HealthDay Reporter , MONDAY, Sept. 26 (HealthDay ... face a higher risk of dying from heart disease than ... findings also showed a slightly increased risk of cardiovascular trouble ... that the results may indicate a link between infertility and ...
Cached Medicine News:Health News:Cost of U.S. Workers' Health Premiums Surged in 2011 2Health News:Cost of U.S. Workers' Health Premiums Surged in 2011 3Health News:Austen BioInnovation Institute's Accountable Care Community initiative gains national support 2Health News:Modern shift work pattern potentially less harmful to health 2Health News:Penn veterinarian Ralph Brinster awarded National Medal of Science 2Health News:Extra Pounds Linked to Weaker Legs in Older Women 2Health News:Childless Men May Face Higher Heart Disease Risk 2Health News:Childless Men May Face Higher Heart Disease Risk 3
... CMC joint is the most common site for ... the CMC joint without restricting the wrist or ... persons who need to control or reduce subluxation ... perform work and leisure activities without pain. Also ...
... This is an excellent choice to treat ... MCP joint, basal joint arthritis, advanced carpal ... the thumb and wrist. Distal palmar ... flexion and full finger dexterity. Constructed ...
... CTi Wrist OTS is an off-the-shelf wrist orthotic designed ... of 3 pre-set ranges-of-motion (20°,35° and 50°). , ... sprains with TFCC tear-triangular fibrocartilage complex , ... nonunion , Partial tendon rupture , ...
... CTi Wrist Static is a solid, one-piece custom wrist ... stable, neutral position. , ,Indications: , Wrist ... fibrocartilage complex , Coles fracture - distal ... Partial tendon rupture , ORIF - Open ...
Medicine Products: